Inclusion Criteria:  Previously diagnosed acromegaly not adequately controlled by surgery and/or radiation therapy and in whom an appropriate medical treatment with any kind of somatostatin analogs (SSAs) did not control the disease or was not tolerated; Previously diagnosed acromegaly adequately controlled by medical treatment; Signed informed consent to participate in the study.  Exclusion Criteria:  Adequately controlled disease by surgery and/or radiation; Patients with transaminases more than 3 times the upper limit of normal; Hypersensitivity to PEG or any of its ingredients; History of other neoplasms, radiotherapy or chemotherapy in the last 5 years; Clinical or laboratory signs of significant hepatobiliary, or pancreatic disease; Severe infections, surgery, trauma requiring hospitalization within 3 months before enrolment; Severe chronic kidney disease (stage 4-5); Any active blood or rheumatic disorders in the last 5 years; Pregnant or nursing women.